Disease · MONDO_0005339

androgenetic alopecia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. androgenetic alopecia. Diseases, record MONDO_0005339. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005339

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: androgenetic alopecia; Open Targets
Open Targets ID: MONDO_0005339; Open Targets
Other names: alopecia, androgenetic, alopecia, androgenic, alopecia, male pattern, androgenic alopecia, male pattern baldness; Open Targets
Disease Ontology: DOID:0050801; Disease Ontology
Highest stage of its drugs: Approval, for 2 of its 21 drugs, from DailyMed and PMDA; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FINASTERIDE	CHEMBL710	Small molecule	Approval	DailyMed	28	12	12	Drugs and targets
DUTASTERIDE	CHEMBL1200969	Small molecule	Approval	PMDA	9	8	8	Drugs and targets
MINOXIDIL	CHEMBL802	Small molecule	Phase 3	ClinicalTrials.gov	41	41	41	Drugs and targets
CLASCOTERONE	CHEMBL3590187	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
LATANOPROST	CHEMBL1051	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DALOSIRVAT	CHEMBL4650339	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
CETIRIZINE	CHEMBL1000	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
BIMATOPROST	CHEMBL1200963	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IFIDANCITINIB	CHEMBL4594441	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2	https://conductscience.org/library/genes/6616	Drugs and targets
PTGFR	Prostaglandin F2-alpha receptor	2	Prostanoid FP receptor agonist	Phase 3	https://conductscience.org/library/genes/5737	Drugs and targets
SRD5A2	3-oxo-5-alpha-steroid 4-dehydrogenase 2	2	Steroid 5-alpha-reductase 2 inhibitor; Steroid 5-alpha-reductase inhibitor	Approval	https://conductscience.org/library/genes/6716	Drugs and targets
ABCC9	Sulfonylurea receptor 2, Kir6.2	1	Sulfonylurea receptor 2, Kir6.2 opener	Phase 3	https://conductscience.org/library/genes/10060	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor antagonist	Phase 3	https://conductscience.org/library/genes/367	Drugs and targets
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor negative allosteric modulator	Early phase 1	https://conductscience.org/library/genes/1268	Drugs and targets
HRH1	Histamine H1 receptor	1	Histamine H1 receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/3269	Drugs and targets
KCNJ11	Sulfonylurea receptor 2, Kir6.2	1	Sulfonylurea receptor 2, Kir6.2 opener	Phase 3	https://conductscience.org/library/genes/3767	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	1	Phosphodiesterase 5A inhibitor	Unknown	https://conductscience.org/library/genes/8654	Drugs and targets
PTGDR2	Prostaglandin D2 receptor 2	1	G protein-coupled receptor 44 antagonist	Phase 2	https://conductscience.org/library/genes/11251	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials70

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01231607	Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia	Phase 3	917	2012-10-04	Androgenetic Alopecia	DUTASTERIDE, FINASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT03004469	Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia	Phase 3	458	2019-04-19	Alopecia, Androgenetic	FINASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT01325337	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Phase 2	307	2014-04-10	Alopecia, Alopecia, Androgenetic, Baldness	BIMATOPROST, MINOXIDIL	Its record names the disease	ClinicalTrials.gov
NCT01904721	A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)	Phase 2	244	2015-12-09	Alopecia, Alopecia, Androgenetic, Baldness	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT02781311	A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males	Phase 2	169	2019-04-05	Alopecia	SETIPIPRANT	Its record names the disease	ClinicalTrials.gov
NCT00441116	A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia	Phase 3	153	2009-04-22	Alopecia	DUTASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT01831791	A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia	Phase 3	120	2015-03-12	Alopecia	DUTASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT02014584	Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia	Phase 3	117	2017-03-08	Alopecia	DUTASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT02460289	Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia	Not applicable	63	2023-08-01	Male Pattern of Hair Loss, Androgenic Alopecia	MINOXIDIL	Its record names the disease	ClinicalTrials.gov
NCT02460497	Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia	Not applicable	61	2023-08-01	Female Pattern Hair Loss, Androgenic Alopecia	MINOXIDIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 70

See all 70 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dutasteride 0.5 mg vs Placebo: Number of Participants With Treatment-related AEs in the Double-blind Treatment Period	11 of 58	5 of 59	117	NCT02014584	Trial comparisons
Dutasteride 0.5 mg vs Placebo: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period	9 of 58	5 of 59	117	NCT02014584	Trial comparisons
Dutasteride 0.5 mg vs Placebo: Incidence of Premature Discontinuations in the Double-blind Treatment Period	6 of 58	2 of 59	117	NCT02014584	Trial comparisons
Dutasteride 0.5 mg vs Placebo: Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Double-blind Treatment Period	0 of 58	0 of 59	117	NCT02014584	Trial comparisons
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants With Treatment-related AEs in the Open-label Treatment Period	2 of 48	4 of 49	97	NCT02014584	Trial comparisons
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Incidence of Premature Discontinuations in the Open-label Treatment Period	1 of 48	5 of 49	97	NCT02014584	Trial comparisons
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Open-label Treatment Period	0 of 48	0 of 49	97	NCT02014584	Trial comparisons
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants With AE Related to Sexual Function in the Open-label Treatment Period	2 of 48	3 of 49	97	NCT02014584	Trial comparisons
Platelet Rich Plasma vs Minoxidil Foam: Adverse Event of Swelling on Scalp	0 of 19	0 of 19	38	NCT03488108	Trial comparisons
Platelet Rich Plasma vs Minoxidil Foam: Adverse Event of Redness on Scalp	0 of 19	0 of 19	38	NCT03488108	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40654553	RESULT	1	PubMed
38598226	RESULT	1	PubMed
37292551	RESULT	1	PubMed
37166619	RESULT	1	PubMed
37016778	RESULT	1	PubMed
35920739	RESULT	1	PubMed
34099599	RESULT	1	PubMed
32425997	RESULT	1	PubMed
30886475	RESULT	1	PubMed
27659896	RESULT	1	PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005339

GET https://conductscience.org/api/diseases/v1/MONDO_0005339/drugs?page=2

API reference For AI assistants